New Delhi: Jagsonpal Pharmaceuticals Ltd. (Jagsonpal) today announced the execution of a Business Transfer Agreement (“BTA”) with Group Pharmaceuticals Limited (“Group Pharma”) for the acquisition of its Wellness Portfolio on a going-concern basis by way of slump sale. The transaction involves Initial consideration of ₹23.7 crores on closing. Additional consideration linked to FY 2027-28 sales of upto ₹23.0 Crores, subject to a total consideration cap of ₹46.7 Crores. The transaction is expected to be completed on or before 01 November, 2026, subject to fulfilment of the conditions precedent and other terms and conditions stipulated under the BTA.
This business brings in an established portfolio of products and an existing market presence, which we intend to integrate with its existing commercial platform and capabilities while leveraging its existing distribution network to create operating synergies.
Manish Gupta, Managing Director, Jagsonpal, said, ” The acquisition marks another meaningful step in our growth journey. It strengthens our pharmaceutical portfolio and expands our presence across complementary therapeutic segments especially in women healthcare, while remaining consistent with our asset-light and focused approach to growth. We remain focused on pursuing opportunities that complement our existing capabilities and create sustainable, long-term value for all our stakeholders.”
Amrut Medhekar, Chief Operating Officer, Jagsonpal, said, “We are delighted to welcome this portfolio and the employees of the business into our organization, and are fully committed to ensuring their smooth and seamless integration. We are equally excited about this acquisition as we embark on our next phase of growth, expanding our field force, strengthening our pan-India presence and creating significant cross-selling opportunities across our portfolio. Together, we look forward to a seamless transition and unlocking the portfolio’s full growth potential by leveraging our established commercial infrastructure and strong execution capabilities.”
The transaction is subject to the fulfilment of applicable conditions precedent and other customary closing conditions as set out in the BTA.
Think law Advisors represented Jagsonpal as their legal Advisors while Tatva Legal advised Group Pharma on the transaction.
